Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)

Next Previous
Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omecamtiv mecarbil (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms GALACTIC-HF
  • Sponsors Amgen; Cytokinetics

Most Recent Events

  • 18 Nov 2024 Results (n=8,232) assessing the CV outcomes, treatment response and tolerability to OM according to age, presented at the American Heart Association Scientific Sessions 2024
  • 05 Nov 2024 According to a Cytokinetics media release, results of Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction According to Age: the GALACTIC-HF Trial will be presented at the American Heart Association Scientific Sessions 2024 taking place in Chicago, IL from November 16, 2024 - November 18, 2024.
  • 05 Nov 2024 According to a Cytokinetics media release, results of Effect of the Cardiac Myosin Activator Omecamtiv Mecarbil on Risk of Ventricular Arrhythmias in Heart Failure with Reduced Ejection Fraction: the GALACTIC-HF Trial will be presented at the American Heart Association Scientific Sessions 2024 taking place in Chicago, IL from November 16, 2024 - November 18, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top